{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:12Z","timestamp":1792184652977,"version":"4.4.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["F31MH132265"],"award-info":[{"award-number":["F31MH132265"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["T32HD069054"],"award-info":[{"award-number":["T32HD069054"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD099775"],"award-info":[{"award-number":["R01HD099775"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM145383"],"award-info":[{"award-number":["R35GM145383"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40262-023-01294-8","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:02:08Z","timestamp":1695812528000},"page":"1621-1637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients"],"prefix":"10.1007","volume":"62","author":[{"given":"Ethan A.","family":"Poweleit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary L.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel E.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeruesenay","family":"Desta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-3961","authenticated-orcid":false,"given":"Laura B.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"1294_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40501-016-0076-7","volume":"3","author":"FS Hussain","year":"2016","unstructured":"Hussain FS, Dobson ET, Strawn JR. Pharmacologic treatment of pediatric anxiety disorders. Curr Treat Options Psych. 2016;3:151\u201360.","journal-title":"Curr Treat Options Psych."},{"key":"1294_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21037\/tp.2017.08.05","volume":"7","author":"DR Patel","year":"2018","unstructured":"Patel DR, Feucht C, Brown K, Ramsay J. Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners. Transl Pediatr. 2018;7:23\u201355.","journal-title":"Transl Pediatr."},{"key":"1294_CR3","first-page":"26","volume":"18","author":"JB Dwyer","year":"2019","unstructured":"Dwyer JB, Bloch MH. Antidepressants for pediatric patients. Curr Psychiatr. 2019;18:26-42F.","journal-title":"Curr Psychiatr"},{"key":"1294_CR4","doi-asserted-by":"publisher","first-page":"20m1396","DOI":"10.4088\/JCP.20m13396","volume":"81","author":"JR Strawn","year":"2020","unstructured":"Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry. 2020;81:20m1396.","journal-title":"J Clin Psychiatry"},{"key":"1294_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/JCP.0b013e318204b117","volume":"31","author":"DJ Sakolsky","year":"2011","unstructured":"Sakolsky DJ, Perel JM, Emslie GJ, Clarke GN, Wagner KD, Vitiello B, et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol. 2011;31:92\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"1294_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0006-3223(98)00353-9","volume":"46","author":"LL von Moltke","year":"1999","unstructured":"von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiat. 1999;46:839\u201349.","journal-title":"Biol Psychiat"},{"key":"1294_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1124\/dmd.104.002428","volume":"33","author":"RS Obach","year":"2005","unstructured":"Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33:262\u201370.","journal-title":"Drug Metab Dispos"},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, M\u00fcller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127\u201334.","journal-title":"Clin Pharmacol Ther"},{"key":"1294_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gim.2016.87","volume":"19","author":"KE Caudle","year":"2017","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19:215\u201323.","journal-title":"Genet Med"},{"key":"1294_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40262-014-0162-1","volume":"53","author":"M Chang","year":"2014","unstructured":"Chang M, Tybring G, Dahl M-L, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram\/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53:801\u201311.","journal-title":"Clin Pharmacokinet"},{"key":"1294_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","volume":"175","author":"MM Juki\u0107","year":"2018","unstructured":"Juki\u0107 MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. AJP. 2018;175:463\u201370.","journal-title":"AJP"},{"key":"1294_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","volume":"45","author":"LS Br\u00e5ten","year":"2020","unstructured":"Br\u00e5ten LS, Haslemo T, Jukic MM, Ingelman-Sundberg M, Molden E, Kringen MK. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology. 2020;45:570\u20136.","journal-title":"Neuropsychopharmacology"},{"key":"1294_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","volume":"83","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83:322\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1294_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1067\/mcp.2001.116513","volume":"70","author":"J Wang","year":"2001","unstructured":"Wang J. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;70:42\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1294_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.ftd.0000189899.23931.76","volume":"28","author":"I Rudberg","year":"2006","unstructured":"Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. Heterozygous mutation in CYP2C19 significantly increases the concentration\/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit. 2006;28:102\u20135.","journal-title":"Ther Drug Monit"},{"key":"1294_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","volume":"64","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol. 2008;64:1181\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"1294_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1483","author":"K Allegaert","year":"2019","unstructured":"Allegaert K, den Anker J. Ontogeny of phase I metabolism of drugs. The J Clin Pharmacol [Internet]. 2019. https:\/\/doi.org\/10.1002\/jcph.1483.","journal-title":"The J Clin Pharmacol [Internet]"},{"key":"1294_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56:266\u201383.","journal-title":"J Clin Pharmacol"},{"key":"1294_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200746040-00002","volume":"46","author":"N Rao","year":"2007","unstructured":"Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46:281\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"1294_CR20","unstructured":"Food and Drug Administration. Clinical Pharmacology\/Biopharmaceutics Review of Three Pharmacokinetic Studies in Adolescent Children 12-17 Years for Lexapro. (2009) [Internet]. [cited 2023 Feb 3]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pediatric\/21323_Escitalopram_clinpharm_PREA.pdf. Accessed 3 Feb 2023."},{"key":"1294_CR21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1177\/0091270005280860","volume":"45","author":"B S\u00f8gaard","year":"2005","unstructured":"S\u00f8gaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005;45:1400\u20136.","journal-title":"J Clin Pharmacol"},{"key":"1294_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","volume":"37","author":"J Alderman","year":"1998","unstructured":"Alderman J, Wolkow R, Chung M, Johnston HF. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998;37:386\u201394.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1294_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/00004583-200209000-00003","volume":"41","author":"DA Axelson","year":"2002","unstructured":"Axelson DA, Perel JM, Birmaher B, Rudolph GR, Nuss S, Bridge J, et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry. 2002;41:1037\u201344.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1294_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2165\/00003088-199700321-00004","volume":"32","author":"RA Ronfeld","year":"1997","unstructured":"Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;32:22\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"1294_CR25","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","volume":"41","author":"CL DeVane","year":"2002","unstructured":"DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41:1247\u201366.","journal-title":"Clin Pharmacokinet"},{"key":"1294_CR26","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","volume":"48","author":"TJ Walsh","year":"2004","unstructured":"Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166\u201372.","journal-title":"Antimicrob Agents Chemother"},{"key":"1294_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/dmd.109.029769","volume":"38","author":"SB Yanni","year":"2010","unstructured":"Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38:25\u201331.","journal-title":"Drug Metab Dispos"},{"key":"1294_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195\u2013235.","journal-title":"Pharmacopsychiatry"},{"key":"1294_CR29","doi-asserted-by":"crossref","unstructured":"Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51\u201368.","DOI":"10.1002\/cpt.2903"},{"key":"1294_CR30","doi-asserted-by":"crossref","unstructured":"Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy. 2023;43(7):675\u201390.","DOI":"10.1002\/phar.2767"},{"key":"1294_CR31","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bcp.12903","volume":"81","author":"SL Van Driest","year":"2016","unstructured":"Van Driest SL, Marshall MD, Hachey B, Beck C, Crum K, Owen J, et al. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery: Population PK of fentanyl using remnant samples from children. Br J Clin Pharmacol. 2016;81:1165\u201374.","journal-title":"Br J Clin Pharmacol"},{"key":"1294_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jcph.1773","volume":"61","author":"SC Tang Girdwood","year":"2021","unstructured":"Tang Girdwood SC, Tang PH, Murphy ME, Chamberlain AR, Benken LA, Jones RL, et al. Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of \u03b2-lactam antibiotics in critically ill children. J Clin Pharmacol. 2021;61:565\u201373.","journal-title":"J Clin Pharmacol"},{"key":"1294_CR33","unstructured":"Flockhart D, Thacker D, McDonald C, Desta Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine (Updated 2021) [Internet]. [cited 2023 Jan 26]. https:\/\/drug-interactions.medicine.iu.edu\/. Accessed 26 Jan 2023."},{"key":"1294_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"1294_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"1294_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.964758","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu S, Xiao T, Huang S, Li X, Kong W, Yang Y, et al. Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age. Front Pharmacol. 2022;13: 964758.","journal-title":"Front Pharmacol"},{"key":"1294_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12991-017-0140-8","volume":"16","author":"P Oliveira","year":"2017","unstructured":"Oliveira P, Ribeiro J, Donato H, Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17.","journal-title":"Ann Gen Psychiatry"},{"key":"1294_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/JCP.0000000000001080","volume":"39","author":"M Scherf-Clavel","year":"2019","unstructured":"Scherf-Clavel M, Deckert J, Menke A, Unterecker S. Smoking Is associated with lower dose-corrected serum concentrations of escitalopram. J Clin Psychopharmacol. 2019;39:485\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"1294_CR39","doi-asserted-by":"crossref","unstructured":"Ramsey LB, Prows CA, Chidambaran V, Sadhasivam S, Quinn CT, Teusink-Cross A, et al. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children\u2019s Hospital Medical Center. Am J Health-Syst Pharm. 2023;80(13):852\u201359.","DOI":"10.1093\/ajhp\/zxad025"},{"key":"1294_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/cpt.1165","volume":"105","author":"LB Ramsey","year":"2019","unstructured":"Ramsey LB, Prows CA, Zhang K, Salda\u00f1a SN, Sorter MT, Pestian JP, et al. Implementation of pharmacogenetics at cincinnati children\u2019s hospital medical center: lessons learned over 14 years of personalizing medicine. Clin Pharmacol Ther. 2019;105:49\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"1294_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116\u201324.","journal-title":"Clin Transl Sci"},{"key":"1294_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacometrics Syst Pharmacol. 2019;8:525\u201337.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1294_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/psp.2012.4","volume":"1","author":"D Mould","year":"2012","unstructured":"Mould D, Upton R. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet Syst Pharmacol. 2012;1:6.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1294_CR44","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/bcp.13994","volume":"85","author":"P Courlet","year":"2019","unstructured":"Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug\u2013drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019;85:2022\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"1294_CR45","unstructured":"Lexapro [Package Insert] [Internet]. Allergan, Inc. 2021 [cited 2023 Jan 26]. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=13bb8267-1cab-43e5-acae-55a4d957630a. Accessed 26 Jan 2023."},{"key":"1294_CR46","unstructured":"Zoloft [Package Insert] [Internet]. Roerig. 2021 [cited 2023 Jan 26]. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fe9e8b7d-61ea-409d-84aa-3ebd79a046b5. Accessed 26 Jan 2023."},{"key":"1294_CR47","doi-asserted-by":"crossref","unstructured":"Dubois D, Dubois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;XVII(6_2):863\u201371.","DOI":"10.1001\/archinte.1916.00080130010002"},{"key":"1294_CR48","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi-2014-0023\/html","author":"K Claudio-Campos","year":"2015","unstructured":"Claudio-Campos K, Duconge J, Cadilla CL, Rua\u00f1o G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Therapy [Internet]. 2015. https:\/\/doi.org\/10.1515\/dmdi-2014-0023\/html.","journal-title":"Drug Metab Pers Therapy [Internet]"},{"key":"1294_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","volume":"11","author":"AB Koopmans","year":"2021","unstructured":"Koopmans AB, Braakman MH, Vinkers DJ, Hoek HW, Van Harten PN. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry. 2021;11:141.","journal-title":"Transl Psychiatry"},{"key":"1294_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaac.2015.05.004","volume":"54","author":"AL Varigonda","year":"2015","unstructured":"Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors in pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:557\u201364.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1294_CR51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaac.2016.07.768","volume":"55","author":"AL Varigonda","year":"2016","unstructured":"Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2016;55:851-859.e2.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1294_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaac.2018.01.015","volume":"57","author":"JR Strawn","year":"2018","unstructured":"Strawn JR, Mills JA, Sauley BA, Welge JA. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2018;57:235-244.e2.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1294_CR53","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0091270008327538","volume":"49","author":"Y Jin","year":"2009","unstructured":"Jin Y, Pollock BG, Frank E, Florian J, Kirshner M, Fagiolini A, et al. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. J Clin Pharmacol. 2009;49:176\u201384.","journal-title":"J Clin Pharmacol"},{"key":"1294_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10928-015-9457-6","volume":"43","author":"A Akil","year":"2016","unstructured":"Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, et al. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer\u2019s disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016;43:99\u2013109.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1294_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0091270009337946","volume":"50","author":"Y Jin","year":"2010","unstructured":"Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, M\u00fcller DJ, et al. Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure. J Clin Pharmacol. 2010;50:62\u201372.","journal-title":"J Clin Pharmacol"},{"key":"1294_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s002280050163","volume":"51","author":"U Jeppesen","year":"1996","unstructured":"Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Br\u00f8sen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51:73\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"1294_CR57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00004714-200104000-00007","volume":"21","author":"AT Harvey","year":"2001","unstructured":"Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21:161\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"1294_CR58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00007691-200112000-00011","volume":"23","author":"B Carlsson","year":"2001","unstructured":"Carlsson B, Olsson G, Reis M, Walinder J, Nordin C, Lundmark J, et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit. 2001;23:658\u201364.","journal-title":"Ther Drug Monit"},{"key":"1294_CR59","doi-asserted-by":"crossref","unstructured":"Pedersen RS, Noehr-Jensen L, Brosen K. The inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele. Clin Exp Pharmacol Physiol. 2013;40(10):683\u20138.","DOI":"10.1111\/1440-1681.12153"},{"key":"1294_CR60","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/jpm11070615","volume":"11","author":"SE Vaughn","year":"2021","unstructured":"Vaughn SE, Strawn JR, Poweleit EA, Sarangdhar M, Ramsey LB. The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations. J Pers Med. 2021;11:615.","journal-title":"J Pers Med."},{"key":"1294_CR61","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1389200217666151210142051","volume":"17","author":"O Zendulka","year":"2016","unstructured":"Zendulka O, Dovrt\u011blov\u00e1 G, Noskov\u00e1 K, Turjap M, \u0160ulcov\u00e1 A, Hanu\u0161 L, et al. Cannabinoids and cytochrome P450 interactions. CDM. 2016;17:206\u201326.","journal-title":"CDM."},{"key":"1294_CR62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bcpt.12938","volume":"122","author":"M Saiz-Rodr\u00edguez","year":"2018","unstructured":"Saiz-Rodr\u00edguez M, Belmonte C, Rom\u00e1n M, Ochoa D, Koller D, Taleg\u00f3n M, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin Pharmacol Toxicol. 2018;122:501\u201311.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1294_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fped.2019.00016","volume":"7","author":"NJ Hanan","year":"2019","unstructured":"Hanan NJ, Paul ME, Huo Y, Kapetanovic S, Smith E, Siberry G, et al. Sertraline pharmacokinetics in hiv-infected and uninfected children, adolescents, and young adults. Front Pediatr. 2019;7:16.","journal-title":"Front Pediatr"},{"key":"1294_CR64","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2165\/00003088-200544110-00005","volume":"44","author":"Y Ishizawa","year":"2005","unstructured":"Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet. 2005;44:1179\u201389.","journal-title":"Clin Pharmacokinet"},{"key":"1294_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/0091270012445793","volume":"53","author":"CH Li","year":"2013","unstructured":"Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, et al. Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 Study. J Clin Pharmacol. 2013;53:234\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1294_CR66","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11096-016-0259-8","volume":"38","author":"N Yuce-Artun","year":"2016","unstructured":"Yuce-Artun N, Baskak B, Ozel-Kizil ET, Ozdemir H, Uckun Z, Devrimci-Ozguven H, et al. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016;38:388\u201394.","journal-title":"Int J Clin Pharm"},{"key":"1294_CR67","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1089\/cap.2019.0017","volume":"29","author":"EA Poweleit","year":"2019","unstructured":"Poweleit EA, Aldrich SL, Martin LJ, Hahn D, Strawn JR, Ramsey LB. Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders. J Child Adolesc Psychopharmacol. 2019;29:348\u201361.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1294_CR68","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/FTD.0000000000000101","volume":"37","author":"C Gjestad","year":"2015","unstructured":"Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37:90\u20137.","journal-title":"Ther Drug Monit"},{"key":"1294_CR69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1208\/s12248-020-00455-y","volume":"22","author":"AA Alhadab","year":"2020","unstructured":"Alhadab AA, Brundage RC. Population pharmacokinetics of sertraline in healthy subjects: a model-based meta-analysis. AAPS J. 2020;22:73.","journal-title":"AAPS J"},{"key":"1294_CR70","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246\u201351.","journal-title":"Epilepsia"},{"key":"1294_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fphar.2019.00099","volume":"10","author":"SL Aldrich","year":"2019","unstructured":"Aldrich SL, Poweleit EA, Prows CA, Martin LJ, Strawn JR, Ramsey LB. Influence of CYP2C19 metabolizer status on escitalopram\/citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol. 2019;10:99.","journal-title":"Front Pharmacol"},{"key":"1294_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.972141","volume":"13","author":"L Eichentopf","year":"2022","unstructured":"Eichentopf L, Hiemke C, Conca A, Engelmann J, Gerlach M, Havemann-Reinecke U, et al. Systematic review and meta-analysis on the therapeutic reference range for escitalopram: blood concentrations, clinical effects and serotonin transporter occupancy. Front Psychiatry. 2022;13: 972141.","journal-title":"Front Psychiatry."},{"key":"1294_CR73","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/cap.2016.0198","volume":"27","author":"JR Strawn","year":"2017","unstructured":"Strawn JR, Dobson ET, Mills JA, Cornwall GJ, Sakolsky D, Birmaher B, et al. Placebo response in pediatric anxiety disorders: results from the child\/adolescent anxiety multimodal study. J Child Adolesc Psychopharmacol. 2017;27:501\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1294_CR74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"key":"1294_CR75","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/cpt.1658","volume":"107","author":"BK Beaulieu-Jones","year":"2020","unstructured":"Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107:843\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"1294_CR76","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","volume":"359","author":"JT Walkup","year":"2008","unstructured":"Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359:2753\u201366.","journal-title":"N Engl J Med"},{"key":"1294_CR77","doi-asserted-by":"publisher","first-page":"5309588","DOI":"10.1155\/2021\/5309588","volume":"2021","author":"W Liu","year":"2021","unstructured":"Liu W, Li G, Wang C, Wang X, Yang L. Efficacy of sertraline combined with cognitive behavioral therapy for adolescent depression: a systematic review and meta-analysis. Comput Math Methods Med. 2021;2021:5309588.","journal-title":"Comput Math Methods Med"},{"key":"1294_CR78","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jad.2021.10.047","volume":"298","author":"JR Strawn","year":"2022","unstructured":"Strawn JR, Mills JA, Suresh V, Peris TS, Walkup JT, Croarkin PE. Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety. J Affect Disord. 2022;298:292\u2013300.","journal-title":"J Affect Disord"},{"key":"1294_CR79","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/da.22329","volume":"32","author":"JR Strawn","year":"2015","unstructured":"Strawn JR, Welge JA, Wehry AM, Keeshin BR, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32:149\u201357.","journal-title":"Depress Anxiety"},{"key":"1294_CR80","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/cts.13216","volume":"15","author":"SL Stancil","year":"2022","unstructured":"Stancil SL, Tumberger J, Strawn JR. Target to treatment: a charge to develop biomarkers of response and tolerability in child and adolescent psychiatry. Clin Transl Sci. 2022;15:816\u201323.","journal-title":"Clin Transl Sci"},{"key":"1294_CR81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/mp.2008.116","volume":"15","author":"M Kato","year":"2010","unstructured":"Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473\u2013500.","journal-title":"Mol Psychiatry"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01294-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01294-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01294-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:34:24Z","timestamp":1697556864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01294-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01294-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"27 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LBR has received research support from BTG International. JRS has received research support from Abbvie, the National Institutes of Health, PCORI, the Yung Family Foundation, and receives material support from Myriad. He receives royalties from UpToDate and Cambridge and has consulted with Cerevel, Otsuka, and Intracellular Therapeutics. All other authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures\/Conflicts of Interest"}},{"value":"Funding from the Center for Pediatric Genomics at Cincinnati Children\u2019s Hospital Medical Center supported this project. EAP is supported by the National Institute of Mental Health of the National Institutes of Health under award number F31MH132265. ZLT was supported by the National Institute of Child Health and Development T32 Cincinnati Pediatric Clinical Pharmacology Training Program (T32HD069054). ZD is supported by R35GM145383 from NIGMS. JRS, EAP, and LBR are supported by NICHD (R01HD099775).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding Information"}},{"value":"Data for this study may be available upon reasonable request from the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This study was approved by the Institutional Review Board at Cincinnati Children\u2019s Hospital Medical Center and was determined to be exempt in accordance with applicable regulations and institutional policy.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"A waiver of informed consent was granted by the IRB at Cincinnati Children\u2019s Hospital Medical Center.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The code generated for the analysis may be available upon reasonable request from the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Data collection was performed by EAP, SEV, and ZD. Data analysis was performed by EAP, ZLT, and TM. The first draft of the manuscript was written by EAP and all authors edited and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}